Posted on June 26, 2020 by Sitemaster
The American Urological Association (AUA), together with the American Society for Radiation Oncology (ASTRO) and the Society for Urologic Oncology (SUO), has just issued a new set of guidelines for the management of advanced prostate cancer (see here). … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: advanced, biochemical, castration-resistant, guideline, hormone-sensitive, metastatic, recurrence | 8 Comments »
Posted on February 7, 2020 by Sitemaster
So your sitemaster has been looking through the full report from the APCCC meeting held in Basel last year — as he promised he would. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: advanced, castration-resistant, consensus, hormone-naive, hormone-sensitive, mCRPC, metastatic, mHSPC, nmCRPC, nmHSPC, non-metastatic | 2 Comments »
Posted on December 17, 2019 by Sitemaster
Yesterday the U.S. Food and Drug Administration (FDA) approved the use of enzalutamide (Xtandi) for the treatment of metastatic, hormone-sensitive prostate cancer (mHSPC) — also known as metastatic, castration-rsensitive prostate cancer or mCSPC. … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: enzalutamide, hormone-sensitive, HSPC, metastatic, Xtandi | 3 Comments »
Posted on June 2, 2019 by Sitemaster
The randomized, double-blind, Phase III ENZAMET trial was designed to investigate whether the combination of enzalutamide + standard androgen suppression had superior outcomes than a non-steroidal antiandrogen + standard androgen suppression in men with metastatic, hormone-sensitive prostate cancer (mHSPC). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: antiandrogen, enzalutamide, ENZAMET, hormone-sensitive, metastatic, mHSPC, non-steroidal, overall, survival | 15 Comments »
Posted on May 31, 2019 by Sitemaster
At the end of January, we had reported that the results of the TITAN trial — the Phase III trial of standard ADT + apalutamide (Erlead) or standard ADT + a placebo in men with metastatic, hormone-sensitive prostate cancer (mHSPC) — were positive, and that they were going to be reported at a meeting later in the year. … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: apalutamide, Erleada, hormone-sensitive, metastatic, mHSPC | 12 Comments »
Posted on May 11, 2019 by Sitemaster
The results of the 1,125-patient, randomized, double-blind ENZAMET trial are to be reported in a late-breaking abstract at the upcoming annual meeting of the American Society for Clinical Oncology (ASCO) in Chicago. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, ENZAMET, enzlutamide, hormone-sensitive, latitude, metastatic, mHSPC, outcome | 9 Comments »
Posted on April 19, 2019 by Sitemaster
Long-term follow-up data from the LATITUDE trial have now been published by Fizazi et al. in Lancet Oncology. … READ MORE …
Filed under: Uncategorized | Tagged: "high risk", abiraterone, ADT, hormone-sensitive, latitude, metastatic, newly diagnosed, survival | 4 Comments »
Posted on February 15, 2019 by Sitemaster
On Thursday, here in San Francisco, Dr. Andrew Armstrong first presented the results of the so-called ARCHES trial of enzalutamide (Xtandi) + standard androgen deprivation therapy (ADT) in the treatment of men with metastatic, “hormone-sensitive” prostate cancer (mHSPC). … READ MORE …
Filed under: Uncategorized | Tagged: ADT, ARCHES, enzalutamide, hormone-sensitive, metastatic, mHSPC, Xtandi | 4 Comments »
Posted on January 31, 2019 by Sitemaster
According to a media release issued late yesterday by Johnson & Johnson, the combination of apalutamide (Erleada) + androgen deprivation therapy (ADT) has met the primary study endpoints in the so-called TITAN trial. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: apalutamide, castration-sensitive, Erleada, hormone-sensitive, mCSPC, metastatic, mHSPC, outcome, TITAN, trial | Leave a comment »
Posted on October 25, 2018 by Sitemaster
Like other, similar drugs before it, ODM-201 — now properly known by the generic name darolutamide — has apparently hit the primary goal of metastasis-free survival in the Phase III ARAMIS trial, as announced yesterday by Bayer and Orion. … READ MORE …
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: castration-resistant, darolutamide, hormone-sensitive, metastatic, non-metastatic, ODM-201 | 4 Comments »
Posted on August 24, 2018 by Sitemaster
We note that Pfizer and Astellas have recently modified the protocols for two large, international, randomized, Phase III clinical trials to see if they can get earlier results that might affect the potential for use of enzalutamide (Xtandi) in some groups of men with hormone-sensitive prostate cancer (HSPC). … READ MORE …
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: "high risk", ARCHES, EMBARK, enzalutamide, hormone-sensitive, metastatic, trial | 6 Comments »
Posted on May 31, 2018 by Sitemaster
A new paper in the Annals of Oncology has addressed the critical question regarding what might be “the best” way we currently have to start treatment for a man newly diagnosed with metastatic, hormone-sensitive prostate cancer (mHSPC). … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: first line, hormone-sensitive, metastatic, Treatment | 8 Comments »
Posted on April 3, 2018 by Sitemaster
New guidelines on the management of metastatic, hormone-sensitive prostate cancer have just been released by the American Society for Clinical Oncology (ASCO), based primarily on data from the CHAARTED, STAMPEDE, and LATITUDE trial data. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: guideline, hormone-sensitive, metastatic, Treatment | 2 Comments »
Posted on February 8, 2018 by Sitemaster
Late yesterday the US Food and Drug Administration announced the approval of abiraterone acetate (Zytiga) + prednisone for the treatment of men with “high-risk, castration-sensitive”, metastatic prostate cancer. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, castration-sensitive, hormone-sensitive, Zytiga | Leave a comment »
Posted on February 1, 2018 by Sitemaster
At the time of the original presentation of data from the CHAARTED trial, the median follow-up for patients enrolled in this trial was 28.9 months. We now have data from the same 790 patients followed for a median of 53.7 months. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: CHAARTED, follow-up. long-term, hormone-sensitive, metastatic | 10 Comments »